Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages
Inhibitors of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), for example tetrazole, styrylpyrazole, phenylfuran, phenylthiophene, phenylpyrrazole, pyrazolecarboxamide, 2-thioacetamide and azo compounds, are useful for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for preventing and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, notably for preventing and/or limiting canities.
1. A regime or regimen for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, comprising administering to a mammalian organism in need of such treatment, a thus effective amount of at least one inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) of formula (I), or salt thereof:
in which:
Hy is a heterocycle having 4, 5, 6 or 7 atoms, optionally comprising at least one carbonyl function and/or one thiocarbonyl function, said heterocycle being optionally substituted with at least one substituent selected from the group consisting of a halogen, the groups OR, SR, NRR′, COR, CSR, NRCONR′R″, C(═NR)R′, C(═NR)NR′R″, NRC(═NR′)NR″R′″, OCOR, COSR, SCOR, CSNRR′, NRCSR′, NRCSNR′R″, COOR, CONRR′, CF 3 , CN, NRCOR′, SO 2 R′, SO 2 NRR′ or NRSO 2 R′, saturated or unsaturated, linear or branched C 1 -C 20 alkyl radicals, and saturated or unsaturated rings having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the alkyl radicals and the rings may be substituted, wherein R, R′, R″ and R′″, which may be identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted;
G is O;
R 1 , R 2 and R 3 represent, independently of one another, a hydrogen, a halogen, a group OR 0 , SR 0 , NR 0 R′ 0 , COR 0 , CSR 0 , NR 0 CONR′ 0 R″ 0 , C(═NR 0 )R′ 0 , C(═NR 0 )NR′ 0 R″ 0 , NR 0 C(═NR′ 0 )NR″ 0 R′″ 0 , OCOR 0 , COSR 0 , SCOR 0 , CSNR 0 R′ 0 , NR 0 CSR′ 0 , NR 0 CSNR′ 0 R″ 0 , COOR 0 , CONR 0 R′ 0 , CF 3 , NO 2 , CN, NR 0 COR′ 0 , SO 2 R′ 0 , SO 2 NR 0 R′ 0 or NR 0 SO 2 R′ 0 , a saturated or unsaturated, linear or branched C 1 -C 20 alkyl radical, or at least one saturated or unsaturated ring having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the rings may be separated or attached, also with the proviso that the alkyl radicals and the rings may be substituted, wherein R 0 , R′ 0 , R″ 0 and R′″ 0 , which may identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted,
wherein said inhibitor also has prostaglandin synthase-inhibiting activity, and the ratio of the 15-PGDH-inhibiting activity of said at least one inhibitor of 15-PGDH to the prostaglandin synthase-inhibiting activity thereof is greater than 1.
2. The regime or regimen as defined by claim 1 , for limiting canities.
3. The regime or regimen as defined by claim 1 , said at least one inhibitor of 15-PGDH being encapsulated in microspheres, nanospheres, oleosomes or nanocapsules.
4. The regime or regimen as defined by claim 1 , said at least one inhibitor of 15-PGDH comprising an inhibitor specific for 15-PGDH type 1.
5. The regime or regimen as defined by claim 1 , comprising topically applying said at least one inhibitor of 15-PGDH onto the skin, the head hair and/or body hair of said mammalian organism.
6. The regime or regimen as defined by claim 1 , said ratio being at least 3:1.
7. The regime or regimen as defined by claim 1 , said ratio being at least 5:1.
8. The regime or regimen as defined by claim 1 , said ratio being at least 10:1.
9. The regime or regimen as defined by claim 1 , said ratio being at least 15:1.
10. The regime or regimen as defined by claim 1 , said ratio being at least 25:1.
11. A regime or regimen for stimulating the production of melanin by the melanocytes, comprising administering to a mammalian organism in need of such treatment, a thus effective amount of at least one inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) of formula (I), or salt thereof:
in which:
Hy is a heterocycle having 4, 5, 6 or 7 atoms, optionally comprising at least one carbonyl function and/or one thiocarbonyl function, said heterocycle being optionally substituted with at least one substituent selected from the group consisting of a halogen, the groups OR, SR, NRR′, COR, CSR, NRCONR′R″, C(═NR)R′, C(═NR)NR′R″, NRC(═NR′)NR″R′″, OCOR, COSR, SCOR, CSNRR′, NRCSR′, NRCSNR′R″, COOR, CONRR′, CF 3 , CN, NRCOR′, SO 2 R′, SO 2 NRR′ or NRSO 2 R′saturated or unsaturated, linear or branched C 1 -C 20 alkyl radicals, and saturated or unsaturated rings having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the alkyl radicals and the rings may be substituted, wherein R, R′, R″ and R′″, which may be identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted;
G is O;
R 1 , R 2 and R 3 represent, independently of one another, a hydrogen, a halogen, a group OR 0 , SR 0 , NR 0 R′ 0 , COR 0 , CSR 0 , NR 0 CONR′ 0 R″ 0 , C(═NR 0 )R′ 0 , C(═NR 0 )NR′ 0 R″ 0 , NR 0 C(═NR′ 0 )NR″ 0 R′″ 0 , OCOR 0 , COSR 0 , SCOR 0 , CSNR 0 R′ 0 , NR 0 CSR′ 0 , NR 0 CSNR′ 0 R″ 0 , COOR 0 , CONR 0 R′ 0 , CF 3 , NO 2 , CN, NR 0 COR′ 0 , SO 2 R′ 0 , SO 2 NR 0 R′ 0 or NR 0 SO 2 R′ 0 , a saturated or unsaturated, linear or branched C 1 -C 20 alkyl radical, or at least one saturated or unsaturated ring having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the rings may be separated or attached, also with the proviso that the alkyl radicals and the rings may be substituted, wherein R 0 , R′ 0 , R″ 0 and R′″ 0 , which may identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted,
wherein said inhibitor also has prostaglandin synthase-inhibiting activity, and the ratio of the 15-PGDH-inhibiting activity of said at least one inhibitor of 15-PGDH to the prostaglandin synthase-inhibiting activity thereof is greater than 1.
12. The regime or regimen as defined by claim 1 , comprising coadministering at least one active agent for promoting pigmentation of the head and/or body hair that is other than said at least one inhibitor of 15-PGDH.
13. The regime or regimen as defined by claim 1 , comprising coadministering at least one penetration-accelerating agent.
14. The regime or regimen as defined by claim 1 , comprising coadministering at least one prostaglandin or prostaglandin derivative.
15. A regime or regimen for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, comprising administering to a mammalian organism in need of such treatment, a thus effective amount of at least one inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), said at least one inhibitor of 15-PGDH comprising at least one heterocyclic compound of formula (I), or salt thereof:
in which:
Hy is a heterocycle having 4, 5, 6 or 7 atoms, optionally comprising at least one carbonyl function and/or one thiocarbonyl function, said heterocycle being optionally substituted with at least one substituent selected from the group consisting of a halogen, the groups OR, SR, NRR′, COR, CSR, NRCONR′R″, C(═NR)R′, C(═NR)NR′R″, NRC(═NR′)NR″R′″, OCOR, COSR, SCOR, CSNRR′, NRCSR′, NRCSNR′R″, COOR, CONRR′, CF 3 , CN, NRCOR′, SO 2 R′, SO 2 NRR′ or NRSO 2 R′saturated or unsaturated, linear or branched C 1 -C 20 alkyl radicals, and saturated or unsaturated rings having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the alkyl radicals and the rings may be substituted, wherein R, R′, R″ and R′″, which may be identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted;
G is O;
R 1 , R 2 and R 3 represent, independently of one another, a hydrogen, a halogen, a group OR 0 , SR 0 , NR 0 R′ 0 , COR 0 , CSR 0 , NR 0 CONR′ 0 R″ 0 , C(═NR 0 )R′ 0 , C(═NR 0 )NR′ 0 R″ 0 , NR 0 C(═NR′ 0 )NR″ 0 R′″ 0 , OCOR 0 , COSR 0 , SCOR 0 , CSNR 0 R′ 0 , NR 0 CSR′ 0 ,NR 0 CSNR′ 0 R″ 0 , COOR 0 , CONRR′ 0 , CF 3 , NO 2 , CN, NR 0 COR′ 0 , SO 2 R′ 0 , SO 2 NR 0 R′ 0 or NR 0 SO 2 R′ 0 , a saturated or unsaturated, linear or branched C 1 -C 20 alkyl radical, or at least one saturated or unsaturated ring having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the rings may be separated or attached, also with the proviso that the alkyl radicals and the rings may be substituted, wherein R 0 , R′ 0 , R″ 0 and R′″ 0 , which may identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted.
16. A regime or regimen for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, comprising administering to a mammalian organism in need of such treatment, a thus effective amount of at least one inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) of formula (I), or salt thereof:
in which:
Hy is a heterocycle having 4, 5, 6 or 7 atoms, optionally comprising at least one carbonyl function and/or one thiocarbonyl function, said heterocycle being optionally substituted with at least one substituent selected from the group consisting of a halogen, the groups OR, SR, NRR′, COR, CSR, NRCONR′R″, C(═NR)R′, C(═NR)NR′R″, NRC(═NR′)NR″R′″, OCOR, COSR, SCOR, CSNRR′, NRCSR′, NRCSNR′R″, COOR, CONRR′, CF 3 , CN, NRCOR′, SO 2 R′, SO 2 NRR′ or NRSO 2 R′saturated or unsaturated, linear or branched C 1 -C 20 alkyl radicals, and saturated or unsaturated rings having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the alkyl radicals and the rings may be substituted, wherein R, R′, R″ and R′″, which may be identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted;
G is O;
R 1 , R 2 and R 3 represent, independently of one another, a hydrogen, a halogen, a group OR 0 , SR 0 , NR 0 R′ 0 , COR 0 , CSR 0 , NR 0 CONR′ 0 R″ 0 , C(═NR 0 )R′ 0 , C(═NR 0 )NR′ 0 R″ 0 , NR 0 C(═NR′ 0 )NR″ 0 R′″ 0 , OCOR 0 , COSR 0 , SCOR 0 , CSNR 0 R′ 0 , NR 0 CSR′ 0 , NR 0 CSNR′ 0 R″ 0 , COOR 0 , CONR 0 R′ 0 , CF 3 , NO 2 , CN, NR 0 COR′ 0 , SO 2 R′ 0 , SO 2 NR 0 R′ 0 or NR 0 SO 2 R′ 0 , a saturated or unsaturated, linear or branched C 1 -C 20 alkyl radical, or at least one saturated or unsaturated ring having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the rings may be separated or attached, also with the proviso that the alkyl radicals and the rings may be substituted, wherein R 0 , R′ 0 , R″ 0 and R′″ 0 , which may identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted,
and co-administering at least one prostaglandin or prostaglandin derivative, said at least one prostaglandin or derivative thereof being selected from the group consisting of prostaglandin PGE1, PGE2, the salts and esters thereof, analogs and derivatives thereof, prostaglandin F2-alpha receptor (FP-R) agonists, latanoprost, fluprostenol, cloprostenol, travoprost or bimatoprost, prostaglandin E2 receptor (EP1-R, EP2-R, EP3-R, EP4-R) agonists, 17-phenyl PGE2, viprostol, butaprost, misoprostol, sulprostone, 16,16-dimethyl PGE2, 11-deoxy-PGE1 or 1-deoxy-PGE1, prostacyclin (IP) receptor agonists and esters thereof, cicaprost, iloprost, isocarbacycline or beraprost, prostaglandin D2 receptor agonists and esters thereof, BW245C ((4S)-(3-[(3R,S)-3-cyclohexyl-3-isopropyl]-2,5-dioxo)4-imidazolidineheptanoic acid) or ((4R)-(3-[(3R,S)-3-cyclohexyl-3-isopropyl]-2,5-dioxo)-4-imidazolidine-heptanoic acid), or thromboxane A2 (TP) receptor agonists, I-BOP ([1S-[1a,2a(Z),3b( 1E, 3S),4a]]-7-[3-[3-hydroxy-4-[4-(iodophenoxy)- 1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid, precursors of these compounds and esters and derivatives thereof.
17. The regime or regimen as defined by claim 1 , said at least one inhibitor of 15-PGDH comprising PhCL28A or a thiazolidinedione.
18. A cosmetic/dermatological composition suited for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, comprising a thus effective amount of at least one inhibitor of 15-PGDH of formula (I), or salt thereof:
in which:
Hy is a heterocycle having 4, 5, 6 or 7 atoms, optionally comprising at least one carbonyl function and/or one thiocarbonyl function, said heterocycle being optionally substituted with at least one substituent selected from the group consisting of a halogen, the groups OR, SR, NRR′, COR, CSR, NRCONR′R″, C(═NR)R′, C(═NR)NR′R″, NRC(═NR′)NR″R′″, OCOR, COSR, SCOR, CSNRR′, NRCSR′, NRCSNR′R″, COOR, CONRR′, CF 3 , CN, NRCOR′, SO 2 R′, SO 2 NRR′ or NRSO 2 R′saturated or unsaturated, linear or branched C 1 -C 20 alkyl radicals, and saturated or unsaturated rings having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the alkyl radicals and the rings may be substituted, wherein R, R′, R″ and R′″, which may be identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted;
G is O;
R 1 , R 2 and R 3 represent, independently of one another, a hydrogen, a halogen, a group OR 0 , SR 0 , NR 0 R′ 0 , COR 0 , CSR 0 , NR 0 CONR′ 0 R″ 0 , C(═NR 0 )R′ 0 , C(═NR 0 )NR′ 0 R″ 0 , NR 0 C(═NR′ 0 )NR″ 0 R′″ 0 , OCOR 0 , COSR 0 , SCOR 0 , CSNR 0 R′ 0 , NR 0 CSR′ 0 ,NR 0 CSNR′ 0 R″ 0 , COOR 0 , CONR 0 R′ 0 , CF 3 , NO 2 , CN, NR 0 COR′ 0 , SO 2 R′ 0 , SO 2 NR 0 R′ 0 or NR 0 SO 2 R′ 0 , a saturated or unsaturated, linear or branched C 1 -C 20 alkyl radical, or at least one saturated or unsaturated ring having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the rings may be separated or attached, also with the proviso that the alkyl radicals and the rings may be substituted, wherein R 0 , R′ 0 , R″ 0 and R′″ 0 , which may identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted,
formulated into a cosmetically/dermatologically acceptable medium therefor, wherein said inhibitor also has prostaglandin synthase-inhibiting activity, and the ratio of the 15-PGDH-inhibiting activity of said at least one inhibitor of 15-PGDH to the prostaglandin synthase-inhibiting activity thereof is greater than 1.
19. The cosmetic/dermatological composition as defined by claim 18 , said at least one inhibitor of 15-PGDH comprising a tetrazole, styrylpyrazole, phenylfuran, phenylthiophene, phenylpyrrazole, pyrazolecarboxamide, thioacetamide and/or azo compound.
20. The cosmetic/dermatological composition as defined by claim 19 , said at least one inhibitor of 15-PGDH being encapsulated in microspheres, nanospheres, oleosomes or nanocapsules.
21. The cosmetic/dermatological composition as defined by claim 19 , further comprising at least one prostaglandin or prostaglandin derivative.
22. The cosmetic/dermatological composition as defined by claim 19 , further comprising at least one active agent for promoting pigmentation of the head and/or body hair that is other than said at least one inhibitor of 15-PGDH.
23. The cosmetic/dermatological composition as defined by claim 19 , said at least one inhibitor of 15-PGDH being formulated into a topically applicable, cosmetically/dermatologically acceptable medium therefor.
24. The cosmetic/dermatological composition as defined by claim 19 , formulated as a lotion, gel, emulsion, cream, serum, powder, salve, tincture, milk, ointment, spray, shampoo, mascara, foam, syrup, capsules, granules, tablets or conditioner.
25. The regime or regimen of claim 15 , wherein said at least one inhibitor of 15-PGDH comprises at least one heterocyclic compound selected from the group consisting of:
4-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-furyl}benzoic acid—